Chemomab Therapeutics Ltd. - Ordinary shares, no par value per share (CMMB)
CUSIP: 16385C203
Q3 2025 13F Holders as of 30 Sep 2025
- Type / Class
- Equity / Ordinary shares, no par value per share
- Shares outstanding
- 491,982,609
- Total 13F shares
- 390,310
- Share change
- +384,560
- Total reported value
- $1,026,521
- Price per share
- $2.63
- Number of holders
- 10
- Value change
- +$1,011,399
- Number of buys
- 9
Quarterly Holders Quick Answers
What is CUSIP 16385C203?
CUSIP 16385C203 identifies CMMB - Chemomab Therapeutics Ltd. - Ordinary shares, no par value per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
- Newer quarter: Q4 2025
Recent filing periods for CUSIP 16385C203:
Top shareholders of CMMB - Chemomab Therapeutics Ltd. - Ordinary shares, no par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| MORGAN STANLEY |
13D/G
13F
|
Company |
3.2%
|
13,213,260
|
$15,327,382 | -$22,120,527 | 31 Jul 2025 | |
| OrbiMed Israel GP Ltd. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
2,241,274
|
$10,108,146 | — | 03 Jan 2023 | |
| OrbiMed Israel BioFund GP Limited Partnership |
13D/G
|
— |
4.8%
|
969,807
|
$1,328,636 | $0 | 18 Jun 2025 | |
| SPHERA FUNDS MANAGEMENT LTD. |
13D/G
13F
|
Company |
4.8%
|
900,428
|
$1,152,548 | $0 | 31 Mar 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
0.23%
|
940,990
|
$1,091,548 | — | 30 Jun 2025 | |
| Yelin Lapidot Holdings Management Ltd. |
13F
|
Company |
0.14%
|
578,291
|
$670,818 | — | 30 Jun 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.05%
|
213,052
|
$247,141 | — | 30 Jun 2025 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.01%
|
39,875
|
$46,247 | — | 30 Jun 2025 | |
| KESTRA PRIVATE WEALTH SERVICES, LLC |
13F
|
Company |
0.01%
|
31,241
|
$36,240 | — | 30 Jun 2025 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
0.01%
|
26,189
|
$30,379 | — | 30 Jun 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0%
|
20,569
|
$23,860 | — | 30 Jun 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0%
|
13,900
|
$16,124 | — | 30 Jun 2025 | |
| GAMMA Investing LLC |
13F
|
Company |
0%
|
12,811
|
$14,861 | — | 30 Jun 2025 | |
| Dale R. Pfost |
3/4/5
|
Chief Executive Officer, Director |
—
mixed-class rows
|
461,853
mixed-class rows
|
$12,567 | — | 14 Mar 2022 | |
| Donald Marvin. |
3/4/5
|
Executive VP, CFO & COO |
—
mixed-class rows
|
198,875
mixed-class rows
|
$10,054 | — | 16 Mar 2022 | |
| Joel Michael Maryles |
3/4/5
|
Director |
—
mixed-class rows
|
13,317
mixed-class rows
|
$7,203 | — | 24 May 2022 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
1,180
|
$1,369 | — | 30 Jun 2025 | |
| UBS Group AG |
13F
|
Company |
0%
|
397
|
$461 | — | 30 Jun 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
111
|
$129 | — | 30 Jun 2025 |
Institutional Holders of Chemomab Therapeutics Ltd. - Ordinary shares, no par value per share (CMMB) as of Q3 2025
As of 30 Sep 2025,
Chemomab Therapeutics Ltd. - Ordinary shares, no par value per share (CMMB) was held by
10 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
390,310 shares.
The largest 10 holders included
SPHERA FUNDS MANAGEMENT LTD., MORGAN STANLEY, Ikarian Capital, LLC, Stonepine Capital Management, LLC, JANE STREET GROUP, LLC, RHUMBLINE ADVISERS, BNP PARIBAS FINANCIAL MARKETS, GAMMA Investing LLC, UBS Group AG, and SBI Securities Co., Ltd..
This page lists
10
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2025 vs Q4 2025 Across Filers
Q4 2025 holders
14
Q3 2025 holders
10
Holder diff
-4
| Investor | Q4 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q3 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.